The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xanax 250 microgram Tablets

250 microgram(s) Tablet

Pfizer Healthcare IrelandPA0822/141/002

Main Information

Trade NameXanax 250 microgram Tablets
Active SubstancesAlprazolam
Strength250 microgram(s)
Dosage FormTablet
Licence HolderPfizer Healthcare Ireland
Licence NumberPA0822/141/002

Group Information

ATC CodeN05BA Benzodiazepine derivatives
N05BA12 alprazolam

Status

Authorised/WithdrawnAuthorised
Licence Issued01/11/1982
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 4, part 1 to the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0094-145-002
Interchangeable List DocumentPDF of Interchangeable List
« Back